Prof. Milton Brown, Director of drug development center of Georgetown University, the United States visited Yinfeng Biological Group with his assistant Dr. Wang Kan on September 8^th. Sheng Dewei, President of Yinfeng Biological Group, Qu Tingyu, Director of stem cell laboratory, Huang Xinhua, Technical director of Yinfeng Biological Group, Duan Wenyuan, Technical director of Department of Clinical Medicine of Yinfeng Gene Technology Co Ltd, Liu Linlin, Director of General Management Department of Yinfeng Biological Group, and Tanyi, research and development engineer of QiLu Cell Treaty Co., Ltd., warmly welcomed them and accompanied to visit with them.

Professor Brown and his entourage visited Jinan Medicine Valley, Umbilical Cord Blood Bank of Shandong Province and Laboratory of Yinfeng Gene Technology Co., Ltd., getting further understanding of the drug industry in Ji'nan and scientific research and overall strength of Yinfeng Biological Group; and then all the visitors had a cordial discussion in the meeting room Yinfeng Biological Group. The two parties have in-depth communication in research on the field of stem cells.

At the end of the meeting, a Cooperation Framework Agreement had been made between Ji'nan Hi Tech Innovation Service Center and Drug Development Center of Georgetown University. The signing of this agreement had reached a basis for transformation of research and development results, high-quality professionals and experts exchange project.

Professor Brown has experience in drug development for more than 20 years and drugs developed by him include anticancer, anti hypertension, anti viral drugs, and so on. There is a series of compound drugs has function of promoting the survival of neural stem cells, which is of great significance to promote the survival of umbilical cord blood stem cells. The purpose of the visit intended to achieve cooperation with Ji'nan Biomedical High-Tech Industries, in particular, to build a domestic joint laboratory with Yinfeng Biological Group, so that research and clinical application of umbilical cord blood stem cells could be further promoted.